Complement C3 is a novel modulator of the anti-factor VIII immune response

Development of neutralizing antibodies against therapeutic Factor VIII (FVIII) is the most serious complication of the treatment of hemophilia A. There is growing evidence to show the multifactorial origin of the anti-FVIII immune response, combining both genetic and environmental factors. While a r...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Haematologica
Glavni autori: Rayes, Julie, Ing, Mathieu, Delignat, Sandrine, Peyron, Ivan, Gilardin, Laurent, Vogel, Carl-Wilhelm, Fritzinger, David C., Frémeaux-Bacchi, Véronique, Kaveri, Srinivas V., Roumenina, Lubka T., Lacroix-Desmazes, Sébastien
Format: Artigo
Jezik:Inglês
Izdano: Ferrata Storti Foundation 2018
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5792280/
https://ncbi.nlm.nih.gov/pubmed/29146705
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2017.165720
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items